NK Cells in the Treatment of Hematological Malignancies

被引:42
作者
Gonzalez-Rodriguez, Ana P. [1 ,2 ,3 ]
Villa-Alvarez, Monica [2 ,3 ,4 ]
Sordo-Bahamonde, Christian [2 ,3 ,4 ,5 ]
Lorenzo-Herrero, Seila [2 ,3 ,4 ]
Gonzalez, Segundo [2 ,3 ,4 ]
机构
[1] HUCA, Dept Hematol, Oviedo 33011, Spain
[2] IUOPA, Oviedo 33006, Spain
[3] Inst Invest Biosanitaria Principado Asturias IISP, Oviedo 33011, Spain
[4] Univ Oviedo, Dept Funct Biol Immunol, E-33006 Oviedo, Spain
[5] EntreChem SL, Oviedo 33011, Spain
关键词
NK cells; cancer; immunotherapy; hematopoietic stem cell transplantation; checkpoint; CAR-NK; NATURAL-KILLER-CELL; FC-GAMMA-RIIIA; CHEMOTHERAPY PLUS RITUXIMAB; PROGRESSION-FREE SURVIVAL; HODGKIN-LYMPHOMA; PERIPHERAL-BLOOD; NKG2D LIGANDS; PROGNOSTIC-SIGNIFICANCE; ANTI-CD20; ANTIBODY; CLINICAL-OUTCOMES;
D O I
10.3390/jcm8101557
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natural killer (NK) cells have the innate ability to kill cancer cells, however, tumor cells may acquire the capability of evading the immune response, thereby leading to malignancies. Restoring or potentiation of this natural antitumor activity of NK cells has become a relevant therapeutic approach in cancer and, particularly, in hematological cancers. The use of tumor-specific antibodies that promote antibody-dependent cell-mediated cytotoxicity (ADCC) through the ligation of CD16 receptor on NK cells has become standard for many hematologic malignancies. Hematopoietic stem cell transplantation is another key therapeutic strategy that harnesses the alloreactivity of NK cells against cancer cells. This strategy may be refined by adoptive transfer of NK cells that may be previously expanded, activated, or redirected (chimeric antigen receptor (CAR)-NK cells) against cancer cells. The antitumor activity of NK cells can also be boosted by cytokines or immunostimulatory drugs such as lenalidomide or pomalidomide. Finally, targeting immunosubversive mechanisms developed by hematological cancers and, in particular, using antibodies that block NK cell inhibitory receptors and checkpoint proteins are novel promising therapeutic approaches in these malignant diseases.
引用
收藏
页数:23
相关论文
共 167 条
  • [1] Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
    Acebes-Huerta, Andrea
    Huergo-Zapico, Leticia
    Gonzalez-Rodriguez, Ana Pilar
    Fernandez-Guizan, Azahara
    Payer, Angel R.
    Lopez-Soto, Alejandro
    Gonzalez, Segundo
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [2] Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
    Alduaij, Waleed
    Ivanov, Andrei
    Honeychurch, Jamie
    Cheadle, Eleanor J.
    Potluri, Sandeep
    Lim, Sean H.
    Shimada, Kazuyuki
    Chan, Claude H. T.
    Tutt, Alison
    Beers, Stephen A.
    Glennie, Martin J.
    Cragg, Mark S.
    Illidge, Tim M.
    [J]. BLOOD, 2011, 117 (17) : 4519 - 4529
  • [3] Human NK cell education by inhibitory receptors for MHC class I
    Anfossi, Nicolas
    Andre, Pascale
    Guia, Sophie
    Falk, Christine S.
    Roetynck, Sophie
    Stewart, C. Andrew
    Breso, Violette
    Frassati, Coralie
    Reviron, Denis
    Middleton, Derek
    Romagne, Francois
    Ugolini, Sophie
    Vivier, Eric
    [J]. IMMUNITY, 2006, 25 (02) : 331 - 342
  • [4] APOSTOLOPOULOS A, 1990, EUR J HAEMATOL, V44, P39
  • [5] Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation
    Asai, O
    Longo, DL
    Tian, ZG
    Hornung, RL
    Taub, DD
    Ruscetti, FW
    Murphy, WJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (09) : 1835 - 1842
  • [6] Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL
    Awasthi, Aradhana
    Ayello, Janet
    Van de Ven, Carmella
    Elmacken, Mona
    Sabulski, Anthony
    Barth, Matthew J.
    Czuczman, Myron S.
    Islam, Humayun
    Klein, Christian
    Cairo, Mitchell S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (05) : 763 - 775
  • [7] Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation
    Bachanova, Veronika
    Weisdorf, Daniel J.
    Wang, Tao
    Marsh, Steven G. E.
    Trachtenberg, Elizabeth
    Haagenson, Michael D.
    Spellman, Stephen R.
    Ladner, Martha
    Guethlein, Lisbeth A.
    Parham, Peter
    Miller, Jeffrey S.
    Cooley, Sarah A.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (09) : 1602 - 1607
  • [8] Secretory pathways generating immunosuppressive NKG2D ligands New targets for therapeutic intervention
    Baragano Raneros, Aroa
    Suarez-Alvarez, Beatriz
    Lopez-Larrea, Carlos
    [J]. ONCOIMMUNOLOGY, 2014, 3 (04)
  • [9] Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
    Battella, Simone
    Cox, Maria Christina
    Santoni, Angela
    Palmieri, Gabriella
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 99 (01) : 87 - 96
  • [10] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Benson, Don M., Jr.
    Bakan, Courtney E.
    Mishra, Anjali
    Hofmeister, Craig C.
    Efebera, Yvonne
    Becknell, Brian
    Baiocchi, Robert A.
    Zhang, Jianying
    Yu, Jianhua
    Smith, Megan K.
    Greenfield, Carli N.
    Porcu, Pierluigi
    Devine, Steven M.
    Rotem-Yehudar, Rinat
    Lozanski, Gerard
    Byrd, John C.
    Caligiuri, Michael A.
    [J]. BLOOD, 2010, 116 (13) : 2286 - 2294